Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti–PD‐1 therapy

Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti–PD‐1 therapy

Abstract Background Currently, there are no recognized or validated biomarkers to identify hepatocellular carcinoma patients (HCC) likely to benefit from anti–PD‐1 therapy. We evaluated the relationship between neutrophil‐lymphocyte ratio (NLR) and platelet‐lymphocyte ratio (PLR) and survival outcom...

Full description

Bibliographic Details
Main Authors: Sirish Dharmapuri, Umut Özbek, Jung‐Yi Lin, Max Sung, Myron Schwartz, Andrea D. Branch, Celina Ang
Format: Article
Language:English
Published: Wiley 2020-07-01
Series:Cancer Medicine
Subjects:
biomarkers
hepatocellular carcinoma
immunotherapy
neutrophil‐lymphocyte ratio
NLR
platelet‐lymphocyte ratio
Online Access:https://doi.org/10.1002/cam4.3135

Internet

https://doi.org/10.1002/cam4.3135

Similar Items